Showing results (131-140 of 170) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1995
The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphomaD A Stewart, J M Vose, D D Weisenburger, et al.
Bone Marrow Transplantation|February 27, 2001
Predictive factors for long-term engraftment of autologous blood stem cellsP R Duggan, D Guo, J Luider, et al.
Current Oncology (Toronto, Ont.)|March 12, 2016
A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemiaS Lachance, A L Christofides, J K Lee, et al.
Metabolites|March 27, 2024
Daily Injection of the β2 Adrenergic Agonist Clenbuterol Improved Muscle Glucose Metabolism, Glucose-Stimulated Insulin Secretion, and Hyperlipidemia in Juvenile Lambs Following Heat-Stress-Induced Intrauterine Growth RestrictionRachel L Gibbs, James A Wilson, Rebecca M Swanson, et al.
Gene|June 9, 1995
Regions of evolutionary conservation between the rat and human prohibitin-encoding genesM S Altus, C M Wood, D A Stewart, et al.
Molecular and Cellular Biology|March 1, 1991
Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cellsM J Nuell, D A Stewart, L Walker, et al.
Journal of Cellular Physiology|November 1, 1993
Cell cycle activity and expression of prohibitin mRNAA J Roskams, V Friedman, C M Wood, et al.
Human Gene Therapy|October 6, 2000
Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatinC T Chen, J Lin, Q Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacyD A Stewart, D Guo, J A Sutherland, et al.
Bone Marrow Transplantation|April 10, 1999
Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimensD A Stewart, D Guo, D Morris, et al.
Pageof 17